Physician profile
Isma Shah
NPI 1073018693
$3,313.66
in general payments reported to CMS, 2019-2025
20 companies · $1,565 in 2025
The $1,565 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $33.21 · 2023: $331 · 2024: $1,384 · 2025: $1,565.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,057 · Education: $224.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,056.82 |
| Education | $223.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $659.51 | 2023-2025 | Fasenra, Tezspire, Airsupra |
| Regeneron Healthcare Solutions, INC. | $423.89 | 2024-2025 | Dupixent |
| Csl Behring | $399.66 | 2024-2025 | Haegarda, Hizentra, Andembry |
| Glaxosmithkline, LLC. | $315.49 | 2023-2025 | Nucala, Trelegy Ellipta |
| Genentech USA, INC. | $295.03 | 2024-2025 | Xolair |
| Takeda Pharmaceuticals U.S.A., INC. | $206.30 | 2024-2025 | Hyqvia, Cuvitru, Takhzyro |
| Biocryst US Sales Co., LLC | $180.86 | 2024-2025 | Orladeyo |
| Novartis Pharmaceuticals Corporation | $169.12 | 2024-2025 | |
| Genzyme Corporation | $149.84 | 2023-2025 | |
| Ars Pharmaceuticals Operations, INC. | $89.21 | 2025 | Neffy |
| Optinose US, INC. | $75.08 | 2024 | |
| Greer Laboratories, INC. | $61.44 | 2024-2025 | Oralair, Palforzia |
| Grifols USA, LLC | $56.11 | 2024 | Xembify |
| Sanofi-Aventis U.S. LLC | $55.99 | 2025 | |
| Amgen INC. | $41.72 | 2024-2025 | Tezspire |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gc Biopharma USA, INC. | $39.58 | 2024-2025 | Alyglo, Alyglo |
| Covis Pharma Gmbh | $33.21 | 2022 | |
| Pfizer INC. | $21.99 | 2024 | |
| Organon LLC | $21.99 | 2025 | |
| Ionis Pharmaceuticals, INC. | $17.64 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Isma Shah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.